There are currently 957 clinical trials in Birmingham, Alabama looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Alabama at Birmingham, University of Alabama, University of Alabama at Birmingham Cancer Center and University of Alabama-Birmingham. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118
Recruiting
This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in participants with R/R B ALL who have received ≥ 2 prior lines of therapies. The study will consist of 3 parts. Part A monotherapy dose escalation. Part B dose optimisation. Part C Dose expansion at the recommended phase 2 dose (RP2D)
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/28/2025
Locations: Research Site, Birmingham, Alabama
Conditions: B-cell Acute Lymphoblastic Leukemia (B-ALL)
Register for Updates
Neonatal Platelet Transfusion Threshold Trial
NCT06676904
Recruiting
The objective of the NeoPlaTT trial is to test whether, among extremely preterm infants born at 23 0/7 to 26 6/7 weeks' gestation, a lower platelet transfusion threshold, compared to a higher threshold, improves survival without major or severe bleeding up to 40 0/7 weeks' postmenstrual age (PMA).
Gender:
ALL
Ages:
Between 1 hour and 48 hours
Trial Updated:
05/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
Register for Updates
STAND - Study of the AGN1 LOEP SV Kit Compared to PMMA in Patients With Vertebral Compression Fractures
NCT04835428
Recruiting
This is a multicenter, single-blinded, randomized controlled clinical trial evaluating the safety and efficacy of the AGN1 LOEP SV Kit for the treatment of painful vertebral compression fragility fractures (VCFs). The objective of this study is to demonstrate non-inferiority of the AGN1 LOEP SV Kit for the treatment of VCFs to standard of care vertebroplasty treatment using bipedicular injection of PMMA bone cement.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
05/27/2025
Locations: Alabama Clinical Therapeutics, Birmingham, Alabama
Conditions: Vertebral Compression Fracture, Compression Fracture, Vertebral Compression
Register for Updates
Chronic Hypertension and Pregnancy 2 (CHAP2) Pilot Project
NCT05989581
Recruiting
The CHAP2 study is designed to provide preliminary data for a larger multicenter study to assess whether treatment of stage 1 hypertension (HTN) in pregnancy improves maternal and or neonatal outcomes. The primary objective of this pilot study is to determine if anti-HTN treatment to BP\<130/80mmHg in pregnant patients with stage 1 HTN is associated with a difference in birthweight percentile at delivery. Patients with stage 1 hypertension in pregnancy will be randomized to BP goals of \<130/80m... Read More
Gender:
FEMALE
Ages:
Between 14 years and 89 years
Trial Updated:
05/27/2025
Locations: UAB, Birmingham, Alabama
Conditions: Hypertension in Pregnancy
Register for Updates
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
NCT06011499
Recruiting
This clinical trial tests the effectiveness of an online weight loss plus resistance training intervention (iLIVE) to decrease obesity and improve frailty in men with prostate cancer who received androgen deprivation therapy (ADT). Androgen deprivation therapy increases the risk of frailty, weight gain and obesity in prostate cancer survivors. The combination of frailty and obesity can lead to a decrease in quality of life and an increased risk of recurrent falls. Using iLIVE may improve obesity... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Alabama, Birmingham, Alabama
Conditions: Prostate Carcinoma
Register for Updates
PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
NCT06074510
Recruiting
The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer. Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cance... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
05/27/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Prostate Cancer
Register for Updates
Early DHA/ARA Supplementation in Growth-restricted Very Preterm Infants: A Randomized Clinical Trial
NCT06207071
Recruiting
Growth-restricted very preterm infants (VPT) are born without adequate fat mass (FM) deposits and low docosahexaenoic acid (DHA) concentrations. They often experience further declines in DHA concentrations during the initial three weeks post-birth while advancing enteral feeds and receiving lipid supplementation predominantly through parenteral nutrition. These suboptimal enteral and parenteral nutrition practices significantly heighten the risk of faltering postnatal growth. One promising appro... Read More
Gender:
ALL
Ages:
Between 24 hours and 72 hours
Trial Updated:
05/26/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Infant Malnutrition, Light-For-Dates With Signs of Fetal Malnutrition, Premature, Nutrition Disorder, Infant
Register for Updates
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
NCT04587323
Recruiting
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with disease outcomes such as ICU admission, length of ventilatory support, respiratory failure, kidney failure, heart failure, and death.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: COVID-19 Disease
Register for Updates
Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare
NCT05658575
Recruiting
The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/23/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Acute Gout Flare, Gout Attack, Gout Flare, Gouty Arthritis, Gout, Arthritis, Joint Pain
Register for Updates
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
NCT06643728
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of Bimagrumab and Tirzepatide, alone or in combination, in adults with obesity or overweight, with at least one obesity related comorbidity, without Type 2 Diabetes. The study will last about 70 weeks.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/23/2025
Locations: Central Research Associates, Birmingham, Alabama
Conditions: Obesity, Overweight
Register for Updates
Developing an Opioid Taper Intervention Before Total Joint Arthroplasty
NCT05788016
Recruiting
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: UAB Hospital-Highlands, Birmingham, Alabama
Conditions: Arthritis Knee, Arthritis Hip, Chronic Pain
Register for Updates
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
NCT06326476
Recruiting
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/22/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Hidradenitis Suppurativa
Register for Updates